Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
Studies have shown an increased risk of new AIDS/death among injecting drug users (IDU) starting highly active antiretroviral therapy (HAART). Of 3872 patients starting HAART in the EuroSIDA study, 819 were IDU (21.2%). During 14 769 person-years of follow-up, 499 patients progressed to new AIDS/death. Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies.
Mocroft
Amanda
A
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK.
Gatell
Jose
J
Reiss
Peter
P
Ledergerber
Bruno
B
Kirk
Ole
O
Vella
Stefano
S
Blaxhult
Anders
A
Phillips
Andrew N
AN
Lundgren
Jens
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015331:Cohort Studies; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006716:Homosexuality; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000401:mortality*
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors